Non Hodgkin Lymphoma Clinical Trial

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin’s Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus rituximab is more effective than combination chemotherapy alone for non-Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without rituximab in treating patients who have newly diagnosed non-Hodgkin's lymphoma that has not been treated previously.

View Full Description

Full Description

OBJECTIVES: I. Determine whether the addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) increases the failure-free survival of patients with newly diagnosed, previously untreated, aggressive B-cell non-Hodgkin's lymphoma. II. Determine whether the addition of rituximab changes the toxicity profile attributed to CHOP chemotherapy in this patient population.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, histology (diffuse small cleaved cell, diffuse mixed, and diffuse large cell vs immunoblastic large cell, mantle cell, and marginal zone), and risk group (low vs intermediate vs high). Patients enter one of two treatment arms: Arm I: Patients receive rituximab IV on day 1, followed by cyclophosphamide IV, doxorubicin IV, vincristine IV, and oral prednisone for 5 consecutive days beginning on day 3. Arm II: Patients receive cyclophosphamide IV, doxorubicin IV, vincristine IV, and oral prednisone daily for 5 consecutive days beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients will be followed for 3 years.

PROJECTED ACCRUAL: A total of 270 patients (135 per treatment arm) will be accrued for this study within 3 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed, newly diagnosed, aggressive (stage II-IV) B-cell non-Hodgkin's lymphoma, including but not limited to:

Mantle cell
Diffuse large cell
Diffuse mixed cell
Anaplastic large cell (B-cell type)
Diffuse small cleaved cell
Marginal zone lymphoma
CD20 positive
19 years old and over
WHO 0-2
Karnofsky 70-100%
Life expectancy at least 6 months
Absolute neutrophil count greater than 1,000/mm3 (unless due to non-Hodgkin's lymphoma (NHL) bone marrow involvement)
Bilirubin less than 3.0 mg/dL
Alkaline phosphatase less than 3 times upper limit of normal (ULN)
SGOT less than 3 times ULN
Fertile patients must use effective contraception
HIV negative
Nonsteroidal hormones for non-lymphoma related conditions allowed (e.g., insulin for diabetes)

Exclusion Criteria:

No prior T-cell lymphoma
Not pregnant or nursing
No other serious disease or medical condition that would interfere with compliance
No other concurrent chemotherapy
No concurrent corticosteroids (unless for prevention of nausea or vomiting)
No concurrent radiotherapy No other concurrent investigational agents

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Study ID:

NCT00004112

Recruitment Status:

Completed

Sponsor:

University of Nebraska

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Jonsson Comprehensive Cancer Center, UCLA
Los Angeles California, 90095, United States
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Study ID:

NCT00004112

Recruitment Status:

Completed

Sponsor:


University of Nebraska

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.